

This is a repository copy of *Smoking cessation in severe mental illness: : combined long-term quit rates from the UK SCIMITAR trials programme.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/150813/>

Version: Published Version

Article:

Gilbody, Simon orcid.org/0000-0002-8236-6983, Peckham, Emily Jane orcid.org/0000-0002-9377-1968, Bailey, Della orcid.org/0000-0002-6059-2111 et al. (6 more authors) (2019) Smoking cessation in severe mental illness: : combined long-term quit rates from the UK SCIMITAR trials programme. *The British journal of psychiatry*. pp. 1-3. ISSN 1472-1465

<https://doi.org/10.1192/bjp.2019.192>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Short report

Smoking cessation in severe mental illness: combined long-term quit rates from the UK SCIMITAR trials programme

Simon Gilbody, Emily Peckham, Della Bailey, Catherine Arundel, Paul Heron, Suzanne Crosland, Caroline Fairhurst, Catherine Hewitt, Jinshuo Li and members of the SCIMITAR+ collaborative*

Summary

Smoking contributes to health inequalities for people with severe mental illness (SMI). Although smoking cessation interventions are effective in the short term, there are few long-term trial-based estimates of abstinence. The SCIMITAR trials programme includes the largest trial to date of a smoking cessation intervention for people with SMI, but this was underpowered to detect anticipated long-term quit rates. By pooling pilot and full-trial data we found that quit rates were maintained at 12 months (OR = 1.67, 95% CI 1.02–2.73, $P = 0.04$). Policymakers can now be confident that bespoke smoking cessation interventions produce successful short- and long-term quitting.

Declaration of interest

None.

Keywords

Psychotic disorders; statistical methodology; pharmaceutical drug trial; mortality; anthropology.

Copyright and usage

© The Royal College of Psychiatrists 2019.

Life expectancy among people with severe mental illnesses (SMIs) such as schizophrenia and bipolar disorder is reduced by around 20 years.¹ Smoking contributes to this profound health inequality and remains one of the most important modifiable risk factors for early death and poor physical health.² Although the rates of smoking are falling for most sections of the population, the prevalence of smoking remains at around 50% for people with severe mental ill health.³ Recent policy initiatives (including the 2019 NHS Long Term Plan: <https://www.longtermplan.nhs.uk/>) identify smoking cessation for people with SMI as a priority, but there remains uncertainty about how mental health services should deliver smoking cessation interventions.

The UK Smoking Cessation Trials for Severe Mental Ill Health programme was commissioned sequentially in 2009 and 2013 by the UK National Institute for Health Research (NIHR). The trials programme followed the Medical Research Council's complex interventions framework,⁴ by first designing a combined behavioural and pharmacological intervention specifically for people with SMI – the Smoking Cessation Intervention for People with Severe Mental Ill Health (SCIMITAR) – and then undertaking a pilot trial (SCIMITAR),⁵ before embarking on a full-scale randomised controlled trial (RCT) (SCIMITAR+) to determine clinical and cost-effectiveness.⁶

Policymakers find precise longer-term estimates of quitting to be helpful, but the research literature is dominated by small sample sizes and short-term follow-up.⁷ The SCIMITAR+ trial is the largest trial of smoking cessation in SMI to date, and has demonstrated the success of smoking cessation programmes in the short term (6 months).⁶ However, the SCIMITAR+ trial still lacked sufficient power to detect the expected differences in the prespecified primary outcome and might have failed to detect anticipated differences in long-term outcomes (making a type 2 error). In this short report we combine pilot and full-trial data to maximise the power and precision of long-term estimates of smoking cessation.

Method

The design, methods and analysis of the SCIMITAR pilot and SCIMITAR+ trials were registered in the public domain (ISRCTN79497236 and ISRCTN72955454) and have been published elsewhere.^{5,6} Briefly, the pragmatic SCIMITAR trials tested the effectiveness of a manualised combined behavioural and pharmacological intervention for people with SMI who smoked, compared with usual care. Participants received face-to-face behavioural support delivered by a mental health professional and were prescribed quit-smoking medication according to patient choice from a range of medications recommended by the National Centre for Smoking Cessation Training (NCSCT).⁸ Participants mostly chose nicotine replacement as their pharmacological support.

The prespecified primary outcome for both trials was biologically verified 7-day point prevalence abstinence at 12 months post-randomisation (defined as self-reported no smoking in the previous 7 days and an expired carbon monoxide (CO) level of <10 ppm). The SCIMITAR pilot study included 97 participants and the full trial included 526. The SCIMITAR+ full RCT was powered at 80% to detect a relative increase in quitting of 1.7 (an effect size derived from the pilot trial and from our systematic reviews in this area⁹), assuming a control quit rate of 20%, equal randomisation and a two-sided alpha of 0.05. Allowing for 20% loss to follow-up at 12 months required a total of 393 participants to be recruited and randomised. In the final trial, this sample size was exceeded but the control event rate (10%) was lower than anticipated, meaning that statistical power was substantially reduced (*post hoc* power estimated at 35%).

In view of the mirror design (including primary end-point) we maximised precision and power to estimate the 12-month outcome by utilising a *post hoc* meta-analysis to combine the randomised data from both trials in RevMan 5 for Windows. We pooled the primary end-point of both trials using a fixed effects model of dichotomous outcomes (7 day quitting versus smoking). We calculated the pooled estimates of unadjusted quit rates using Mantel-Haenszel odds ratios (ORs) and 95% confidence intervals (CIs), and also pooled estimates of risk difference. We made the most conservative estimate by assuming that all participants

* Members of the SCIMITAR+ collaborative are listed in the Acknowledgements.




Fig. 1 Combined 12-month abstinence, from SCIMITAR pilot and full-trial data.

M-H, Mantel-Haenszel; UC, usual care; BSC, bespoke smoking cessation.

without a 12-month CO measurement were still smokers. In each trial an odds ratio that adjusted for baseline differences in smoking severity had also been reported as the primary outcome, in line with a prespecified data analysis plan. We therefore conducted a sensitivity analysis by meta-analysing adjusted estimates using the inverse variance method.

Results

The combined sample size of the pilot and full SCIMITAR trials was 623, comprising participants with schizophrenia or bipolar disorder. The combined odds ratio of successful quitting was in line with our prespecified estimate and favoured the bespoke SMI smoking cessation intervention (OR = 1.67, 95% CI 1.02–2.73, $P = 0.04$) with no between-study heterogeneity ($I^2 = 0$). Fig. 1 shows a forest plot of 12-month outcomes. The pooled absolute reduction in smoking rate at 12 months was 5.0% (95% CI 0.0–10.0%). A sensitivity analysis utilising adjusted estimates produced a largely consistent pooled odds ratio (OR = 1.76, 95% CI 1.05–2.96, $P = 0.03$).

Discussion

The SCIMITAR trials programme measured long-term quit rates at 12 months using a biologically verified measure of abstinence, but was still underpowered to detect our prespecified estimate despite having planned the sample size in a pilot trial using conventional parameter estimates (80% power, $P < 0.05$, two-sided test). By using the opportunity to pool RCT data drawn from both pilot and trial data, the power and precision of estimates has been maximised. Our main finding is that bespoke smoking cessation resulted in a demonstrable effect at 12 months that we were not able to detect in analysis of single trials. The results of this pooled analysis present convincing evidence drawn from pragmatic trials of the impact of a bespoke intervention designed for people with SMI, and this can be used to formulate policy in this area.

Pilot trials are often used to derive estimates of recruitment and retention in evaluating novel interventions, but also in planning sample size calculations for fully powered trials.¹⁰ The pilot trial of the bespoke smoking cessation intervention⁶ did not correctly predict the baseline event rate and as a result the SCIMITAR+ trial was underpowered to detect our prespecified estimate of successful quitting. The present analysis utilises all trial-based data and represents an additional use of internal pilot-trial data. On the basis of these pooled data, the combined pharmacological and behavioural approach in SCIMITAR forms a candidate intervention to reduce historically elevated smoking rates among people with SMI.¹¹ The challenge is the implementation of research evidence

in mental health services to ensure that effective treatments are offered as a matter of routine.

Simon Gilbody , DPhil, FRCPSych, Professor of Psychological Medicine, Department of Health Sciences, University of York, UK; **Emily Peckham**, PhD, Manager of the SCIMITAR trial and Research Fellow, Department of Health Sciences, University of York, UK; **Della Bailey**, MSc, Research Fellow, Department of Health Sciences, University of York, UK; **Catherine Arundel**, MSc, Trials Coordinator, Department of Health Sciences, University of York, UK; **Paul Heron**, MRes, Research Fellow, Department of Health Sciences, University of York, UK; **Suzanne Crosland**, PG Dip, Research Fellow, Department of Health Sciences, University of York, UK; **Caroline Fairhurst**, MSc, Research Fellow, Department of Health Sciences, University of York, UK; **Catherine Hewitt**, PhD, Professor of Medical Statistics, Department of Health Sciences, University of York, UK; **Jinshuo Li**, MPhil, Research Fellow, Department of Health Sciences, University of York, UK; **members of the SCIMITAR+ collaborative**, see Acknowledgements

Correspondence: Simon Gilbody, Mental Health and Addictions Research Group (MHARG), Department of Health Sciences, University of York, Heslington Hall, Heslington YO10 5DD, UK. Email: simon.gilbody@york.ac.uk

First received 24 Apr 2019, final revision 19 Jul 2019, accepted 26 Jul 2019

Funding

This trial was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project reference 11/136/52). S.G. was funded by the NIHR Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber (NIHR CLAHRC YH). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care.

Acknowledgements

Members of the SCIMITAR+ collaborative: Catherine Hewitt, PhD; Steve Parrott, MSc; Tim Bradshaw, PhD; Michelle Horspool, PhD; Liz Hughes, PhD; Tom Hughes, MD; Suzy Ker, MD; Moira Leahy, MSc; Tayla McCloud, MSc; David Osborn, PhD; Joe Reilly, DM; Thomas Steare, MSc; Emma Ballantyne, BSc; Polly Bidwell, PG Dip; Sue Bonner, PG Cert; Diane Brennan, MSc; Tracy Callen, RGN; Alex Carey, MSc; Charlotte Colbeck, MSc; Debbie Coton, MSc; Emma Donaldson, MSc; Kimberley Evans, BSc; Hannah Herlihy, BSc; Wajid Khan, PhD; Lizwi Nyathi, PG Dip; Elizabeth Nyamadzawo, BSc; Helen Oldknow, PhD; Peter Phiri, PhD; Shanaya Rathod, PhD; Jamie Rea, PG Dip; Crystal-Bella Romain-Hooper, BSc; Kaye Smith, RMN; Alison Stribling, Clin Dip; Carinna Vickers, RGN.

References

- 1 Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. *Br J Psychiatry* 2010; **196**: 116–21.
- 2 Royal College of Physicians, Royal College of Psychiatrists. *Smoking and Mental Health: A Joint Report by the Royal College of Physicians and the Royal College of Psychiatrists*. Royal College of Physicians, 2013.
- 3 Szatkowski L, McNeill A. Diverging trends in smoking behaviors according to mental health status. *Nicotine Tob Res* 2014; **17**: 356–60.
- 4 Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008; **337**: a1655.
- 5 Gilbody S, Peckham E, Man M-S, Mitchell N, Li J, Becque T, et al. Bespoke smoking cessation for people with severe mental ill health (SCIMITAR): a pilot randomised controlled trial. *Lancet Psychiatry* 2015; **2**: 395–402.
- 6 Gilbody S, Peckham E, Bailey D, Arundel C, Heron P, Crosland S, et al. Smoking cessation for people with severe mental illness (SCIMITAR+):

- a pragmatic randomised controlled trial. *Lancet Psychiatry* 2019; **6**: 379–90.
- 7 Peckham E, Brabyn S, Cook L, Tew G, Gilbody S. Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis. *BMC Psychiatry* 2017; **17**: 252.
 - 8 McEwen A, Hajek P, McRobbie H, West R. *Manual of Smoking Cessation: A Guide for Counsellors and Practitioners*. Blackwell Publishing, 2006.
 - 9 Banham L, Gilbody SM. Smoking cessation in severe mental illness: what works? *Addiction* 2010; **105**: 1176–89.
 - 10 Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. *J Eval Clin Pract* 2004; **10**: 307–12.
 - 11 Robson D, McNeill A. Cutting edge smoking cessation support: SCIMITAR+. *Lancet Psychiatry* 2019; **6**: 358–9.